Honors & Awards

  • Rathmann Family Foundation Medical Education Fellowship in Patient-Centered Care, Stanford University (July 2014-June 2015)
  • KL2 Mentored Research Career Development Program Award, Stanford Center for Clinical and Translational Research and Education (September 2013-June 2015)
  • Innovations in Patient Care Grant Recipient, Spectrum Child Health Research Institute, Stanford University (September 2013 - September 2014)

Professional Education

  • Master of Science, Stanford University, EPIDM-MS (2015)
  • MS, Stanford University, Epidemiology and Clinical Research
  • Fellowship, Stanford University, Pediatric Hematology/Oncology
  • Residency, University of Colorado, Children's Hospital Colorado, Pediatrics (2012)
  • MD, Northwestern University Feinberg School of Medicine (2009)
  • Bachelor of Science, Pennsylvania State University (2005)


Graduate and Fellowship Programs


Journal Articles

  • Moderate Aplastic Anemia in Children: Preliminary Outcomes for Treatment Versus Observation From a Single-Institutional Experience JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Brock, K., Goldenberg, N., Graham, D. K., Liang, X., Hays, T. 2013; 35 (2): 148-152


    Because of the variety of definitions used to describe moderate aplastic anemia (MAA), we review our institutional experience period with patients who met a proposed set of criteria for this disorder. On an exploratory basis, we sought to evaluate the influence of treatment with immunosuppressive therapy (IST) versus observation on long-term outcomes.Records from 1999 to 2010 were screened for patients who met the criteria for MAA: (1) bone marrow cellularity of 20% to 50%; (2) cytopenias in at least 1 cell line (absolute neutrophil count<1000/µL, hemoglobin<9 g/dL, platelet count<100,000/µL); (3) mean corpuscular volume ?90; (4) persistence >6 months; and (5) negative Fanconi studies. Data were collected for patient/disease characteristics, treatments, and outcomes.Eight patients met the criteria for MAA. Three of 8 patients received IST. Of 3 patients who received IST, complete response was observed in 2 and transfusion independence in 1, as compared with 2 of 5 and 3 of 5 in the group who were observed without IST. Median duration of follow-up was 48 months.As several patients spontaneously resolved, and none developed severe aplastic anemia, acute myelogenous leukemia, or myelodysplastic syndrome, the criteria used here may identify a group of children with favorable prognosis who can be managed supportively.

    View details for DOI 10.1097/MPH.0b013e3182755f36

    View details for Web of Science ID 000315357100026

    View details for PubMedID 23128338

  • Li-Fraumeni Syndrome, Brock , K., Sakamoto , K. 2013
  • Quantitative analysis of limb anomalies in CHARGE syndrome: Correlation with diagnosis and characteristic CHARGE anomalies AMERICAN JOURNAL OF MEDICAL GENETICS PART A Brock, K. E., Mathiason, M. A., Rooney, B. L., Williams, M. S. 2003; 123A (1): 111-121


    CHARGE syndrome was initially not thought to involve the limb. Several subsequent reports have shown that limb anomalies are not uncommon. To date, there have been no quantitative studies of limb anomalies in CHARGE syndrome. This study was designed to answer several questions: Do CHARGE patients with limb anomalies represent a subgroup within CHARGE syndrome? Are there correlations between certain CHARGE syndrome anomalies and limb anomalies?Are there differences between the two genders and associated limb anomalies? Are certain types of limb anomalies seen with increased frequency in CHARGE syndrome? All described patients were categorized utilizing the AI/GEN Model 2 Criteria proposed by Mitchell [1985a: J Med Syst 9:425-435]. Patients with chromosomal anomalies or familial CHARGE were excluded, as were patients with inadequate clinical descriptions, and patients in large series where individual characteristics could not be ascertained. Multivariate analysis was performed. One hundred seventy two patients with definite or probable CHARGE syndrome were analyzed. Sixty-four (37.2%) of these patients have at least one limb anomaly. Significant positive associations were seen between limb anomalies and ocular coloboma, urinary tract malformations, and genital anomalies. These associations were not significant when the definite or probable patients were analyzed separately, with the exception of genital anomalies in definite CHARGE. Gender differences were also identified. Females with tracheoesophageal fistula/esophageal atresia, or genital anomalies were more likely to have limb anomalies, while some female subgroups had positive associations between urinary tract malformations, or choanal atresia and limb anomalies. Negative associations were also seen with sensorineural hearing loss and facial paralysis. In contrast, males showed a positive association between coloboma and limb anomalies, while subgroup analysis identified positive associations with DiGeorge sequence or genital anomalies and limb anomalies. Limb anomalies are present in just over one-third of CHARGE syndrome patients. Limb anomalies are seen more frequently in association with certain CHARGE anomalies, and these associations show gender differences. There is not a common limb anomaly seen in CHARGE syndrome.

    View details for DOI 10.1002/ajmg.a.20526

    View details for Web of Science ID 000186239400017

    View details for PubMedID 14626219


  • Redefining Hypoplastic Anemia in Children: Preliminary outcomes for treatment versus observation from a single institution experience

    Time Period

    April 2011

    Presented To

    American Society of Pediatric Hematology/Oncology Annual Meeting


    Baltimore, MD

  • Quantitative analysis of limb anomalies in CHARGE syndrome: correlation with diagnosis and characteristic CHARGE anomalies

    Time Period

    November 2003

    Presented To

    American Society of Human Genetics Annual Meeting


    Los Angeles, CA

  • Congenital Peribronchial Myofibroblastic Tumor: Case Report of an Asymptomatic Infant with a Rapidly Enlarging Pulmonary Mass Florette Hazard, Neyssa Marina

    Time Period

    May 2014

    Presented To

    American Society of Pediatric Hematology/Oncology Annual Meeting


    Chicago, IL


    • Florette Hazard, Assistant Professor of Pathology and of Pediatrics at the Stanford University Medical Center
    • Neyssa Marina, Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital

Stanford Medicine Resources: